The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected 2,029,930 people worldwide and caused 136,320 deaths.Unfortunately, however, the scarcity of information about the mechanisms of SARS-CoV2 infection hamper identification of effective therapies or existing FDA approved drugs. This report models current information about the SARS-CoV2 viral proteins and their cellular interacting proteins by comparing the B cell interactomes of BRD4, with or without BET inhibition, or the E protein encoded by SARS-CoV2. Similarities with published cellular interactants of SARS-CoV2 proteins with BRD4-interacting protein candidates, with or without BET inhibition, suggest 61 cellular protein drug targets and 132 FDA approved drugs. Sample testing the model by experimentation confirmed interaction of the E protein of SARS-CoV2 with BRD4, histones, and other chromosome maintenance proteins, and of the Spike (S) protein with CANX. The implications to SARSCoV2 disease diagnosis, therapy and vaccine creation are discussed.
Comparison of the Interactomes of SARS-CoV2 Virus E Protein and BRD4 with Bet-Inhibition – Implications for Repurposing Approved Drugs and Therapeutic Targets